Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Barbare J.,,Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma,2005,Journal of Clinical Oncology,114,10.1200/JCO.2005.05.470,France,Article,Compiegne,0,Journal,2-s2.0-22344452017
Douer D.,,Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies,2005,Journal of Clinical Oncology,201,10.1200/JCO.2005.10.217,United States,Review,Los Angeles,0,Journal,2-s2.0-17144377127
Kim K.,,A phase II trial of arsenic trioxide in patients with metastatic melanoma,2005,Cancer,58,10.1002/cncr.21386,United States,Article,Houston,1,Journal,2-s2.0-26444590898
Yeo W.,,A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma,2005,Journal of the National Cancer Institute,486,10.1093/jnci/dji315,Hong Kong,Article,,1,Journal,2-s2.0-27144557565
Hsu C.,,Recent advances in non-surgical treatment for advanced hepatocellular carcinoma,2004,Journal of the Formosan Medical Association,23,,Taiwan,Review,Taipei,0,Journal,2-s2.0-6344235699
Hsu C.,,Low-dose thalidomide treatment for advanced hepatocellular carcinoma,2003,Oncology,85,10.1159/000074477,Taiwan;Taiwan,Article,Taipei;Taipei,0,Journal,2-s2.0-0344305652
Kito M.,,Antitumor effect of arsenic trioxide in murine xenograft model,2003,Cancer Science,35,10.1111/j.1349-7006.2003.tb01393.x,Japan,Article,Kani District,1,Journal,2-s2.0-0345530942
Barbey J.,,Effect of arsenic trioxide on QT interval in patients with advanced malignancies,2003,Journal of Clinical Oncology,173,10.1200/JCO.2003.10.009,United States,Article,"Washington, D.C.",0,Journal,2-s2.0-0141939058
Mathas S.,,Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis,2003,Blood,147,10.1182/blood-2002-04-1154,Germany,Article,Berlin,0,Journal,2-s2.0-0042744800
Zhang T.,,Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo,2003,Journal of Experimental and Clinical Cancer Research,39,,China;China,Article,Tianjin;Tianjin,0,Journal,2-s2.0-0037352831
Oketani M.,,Inhibition by arsenic trioxide of human hepatoma cell growth,2002,Cancer Letters,67,10.1016/S0304-3835(01)00800-X,Japan,Article,Kagoshima,0,Journal,2-s2.0-0037179548
Vuky J.,,Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma,2002,Investigational New Drugs,68,10.1023/A:1016270206374,United States;United States,Article,New York;New York,0,Journal,2-s2.0-0036021225
Leung T.,,"Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy",2002,Cancer,96,10.1002/cncr.10236,Hong Kong;Hong Kong,Article,;Shatin,1,Journal,2-s2.0-0037080414
Qian J.,,Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer,2001,Zhonghua zhong liu za zhi [Chinese journal of oncology],19,,China,Article,Nanjing,0,Journal,2-s2.0-0035524397
Roboz G.J.,,Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis,2000,Blood,252,10.1182/blood.v96.4.1525,United States,Article,New York,1,Journal,2-s2.0-0034663032
Therasse P.,,New guidelines to evaluate the response to treatment in solid tumors,2000,Journal of the National Cancer Institute,13670,10.1093/jnci/92.3.205,Belgium,Article,Brussels,1,Journal,2-s2.0-0034594628
Lew Y.,,Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown,1999,Cancer Research,126,,United States,Article,Detroit,0,Journal,2-s2.0-0033572313
Niu C.,,"Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients",1999,Blood,496,10.1182/blood.v94.10.3315.422k16_3315_3324,,Article,,0,Journal,2-s2.0-0033570955
Dai J.,,Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system,1999,Blood,512,10.1182/blood.v93.1.268,United States,Article,New York,0,Journal,2-s2.0-0032933610
Llovet J.M.,,Prognosis of hepatocellular carcinoma: The BCLC staging classification,1999,Seminars in Liver Disease,2348,10.1055/s-2007-1007122,Spain,Article,Barcelona,0,Journal,2-s2.0-0032879468
Soignet S.,,Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide,1998,New England Journal of Medicine,1050,10.1056/NEJM199811053391901,United States,Article,New York,0,Journal,2-s2.0-0032487923
Shao W.,,Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells,1998,Journal of the National Cancer Institute,316,10.1093/jnci/90.2.124,Canada,Article,Montreal,1,Journal,2-s2.0-0000531696
Manghisi G.,,A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients,1998,Hepatology,1047,10.1002/hep.510280322,Italy,Article,Bari,0,Journal,2-s2.0-0031782818
Simon R.,,Optimal two-stage designs for phase II clinical trials,1989,Controlled Clinical Trials,2759,10.1016/0197-2456(89)90015-9,United States,Article,Bethesda,0,Journal,2-s2.0-0024536437
LIAW Y.,,Alpha‐fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma,1986,Liver,114,10.1111/j.1600-0676.1986.tb00279.x,Taiwan,Article,Taipei,0,Journal,2-s2.0-0023003223
Okuda K.,,Early recognition of hepatocellular carcinoma,1986,Hepatology,306,10.1002/hep.1840060432,Japan,Article,Chiba,0,Journal,2-s2.0-0022551816
